Cargando…
Alternative Checkpoints as Targets for Immunotherapy
PURPOSE OF REVIEW: Immunotherapy has shown an unprecedented response in treatment of tumors. However, challenges such as lack of cytotoxic lymphocytes to mount an immune response or development of resistance to therapy can limit efficacy. Here, we discuss alternative checkpoints that can be targeted...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608303/ https://www.ncbi.nlm.nih.gov/pubmed/33141349 http://dx.doi.org/10.1007/s11912-020-00983-y |
_version_ | 1783604809308307456 |
---|---|
author | Pant, Ayush Medikonda, Ravi Lim, Michael |
author_facet | Pant, Ayush Medikonda, Ravi Lim, Michael |
author_sort | Pant, Ayush |
collection | PubMed |
description | PURPOSE OF REVIEW: Immunotherapy has shown an unprecedented response in treatment of tumors. However, challenges such as lack of cytotoxic lymphocytes to mount an immune response or development of resistance to therapy can limit efficacy. Here, we discuss alternative checkpoints that can be targeted to improve cytotoxic lymphocyte function while harnessing other components of the immune system. RECENT FINDINGS: Blockade of alternative checkpoints has improved anti-tumor immunity in mouse models and is being tested clinically with encouraging findings. In addition to modulating T cell function directly, alternative checkpoints can also regulate activity of myeloid cells and regulatory T cells to affect anti-tumor response. SUMMARY: Combination of immune checkpoint inhibitors can improve treatment of tumors by activating multiple arms of the immune system. |
format | Online Article Text |
id | pubmed-7608303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-76083032020-11-05 Alternative Checkpoints as Targets for Immunotherapy Pant, Ayush Medikonda, Ravi Lim, Michael Curr Oncol Rep Immuno-oncology (RM Bukowski and JH Finke, Section Editors) PURPOSE OF REVIEW: Immunotherapy has shown an unprecedented response in treatment of tumors. However, challenges such as lack of cytotoxic lymphocytes to mount an immune response or development of resistance to therapy can limit efficacy. Here, we discuss alternative checkpoints that can be targeted to improve cytotoxic lymphocyte function while harnessing other components of the immune system. RECENT FINDINGS: Blockade of alternative checkpoints has improved anti-tumor immunity in mouse models and is being tested clinically with encouraging findings. In addition to modulating T cell function directly, alternative checkpoints can also regulate activity of myeloid cells and regulatory T cells to affect anti-tumor response. SUMMARY: Combination of immune checkpoint inhibitors can improve treatment of tumors by activating multiple arms of the immune system. Springer US 2020-11-03 2020 /pmc/articles/PMC7608303/ /pubmed/33141349 http://dx.doi.org/10.1007/s11912-020-00983-y Text en © Springer Science+Business Media, LLC, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Immuno-oncology (RM Bukowski and JH Finke, Section Editors) Pant, Ayush Medikonda, Ravi Lim, Michael Alternative Checkpoints as Targets for Immunotherapy |
title | Alternative Checkpoints as Targets for Immunotherapy |
title_full | Alternative Checkpoints as Targets for Immunotherapy |
title_fullStr | Alternative Checkpoints as Targets for Immunotherapy |
title_full_unstemmed | Alternative Checkpoints as Targets for Immunotherapy |
title_short | Alternative Checkpoints as Targets for Immunotherapy |
title_sort | alternative checkpoints as targets for immunotherapy |
topic | Immuno-oncology (RM Bukowski and JH Finke, Section Editors) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608303/ https://www.ncbi.nlm.nih.gov/pubmed/33141349 http://dx.doi.org/10.1007/s11912-020-00983-y |
work_keys_str_mv | AT pantayush alternativecheckpointsastargetsforimmunotherapy AT medikondaravi alternativecheckpointsastargetsforimmunotherapy AT limmichael alternativecheckpointsastargetsforimmunotherapy |